ClinicalTrials.gg
CompletedNCT06010004ACHIEVE-JUpdated Jun 30, 2026Results posted

A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes

A Phase 3 interventional study of Orforglipron in Type 2 Diabetes, sponsored by Eli Lilly and Company. Completed at 40 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-30.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
401
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 15 studies testing orforglipron in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, 4 of them phase 3. orforglipron · Diabetes Mellitus, Type 2.

Enrollment
9th of 15
401 · median 546
Started
2023
with 5 others
Phase 3
11 of 15
2 open now
Registered
7th of 15
by date
Lead sponsor
14 of 15
Eli Lilly and Company

Among the 15 studies testing orforglipron in Diabetes Mellitus, Type 2, this one is the 9th largest by enrollment, is one of 6 that started in 2023, is one of 11 in phase 3, and was the 7th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 15 studies testing orforglipron in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About orforglipron

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing orforglipron in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is to determine the long-term safety of the study intervention orforglipron as a monotherapy or in combination with oral antihyperglycemic medication.

This study includes 3 periods as follows:

  • screening and lead-in period: up to 4 weeks
  • treatment period: 52 weeks, including 20 weeks of dose escalation, and
  • safety follow-up period: 2 weeks.
03

Conditions studied

  • Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have Type 2 Diabetes (T2D)
  • Have ≥7.0% (≥53 mmol/mol) to ≤10.5% (≤91 mmol/mol) as determined by the central laboratory at screening.
  • Are of stable weight (±5%) for at least 90 days prior to screening and agree to not initiate an intensive diet or exercise program during the study with the intent of reducing body weight other than the lifestyle and/or dietary measures for diabetes treatment.
  • Have a ≥23.0 kilogram/square meter (kg/m²) at screening.

Exclusion criteria

Exclusion Criteria:

  • Have Type 1 Diabetes (T1D).
  • Have a history of severe hypoglycemia or hypoglycemia unawareness within the last 6 months prior to screening, or between screening and randomization.
  • Have functional classification IV congestive heart failure.
  • Have had any of the following cardiovascular (CV) conditions within 60 days prior to screening, or between screening and randomization.

    • acute myocardial infarction
    • cerebrovascular accident (stroke), or
    • hospitalization for congestive heart failure
  • Have acute or chronic hepatitis and pancreatitis
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
401 participants (actual)

Study arms

  • Experimental
    3 mg Orforglipron

    Participants received once-daily oral orforglipron for 52 weeks. Treatment began with a 1-mg loading dose for the first 4 weeks, followed by the maintenance dose of 3 mg for the remainder of the duration.

    Drug: Orforglipron

  • Experimental
    12 mg Orforglipron

    Participants received once-daily oral orforglipron for 52 weeks. Treatment began with a 1-mg loading dose for the first 4 weeks, followed by dose escalations every 4 weeks to reach the maintenance dose of 12 mg at week 12, which was then continued for the remainder of the duration.

    Drug: Orforglipron

  • Experimental
    36 mg Orforglipron

    Participants received once-daily oral orforglipron for 52 weeks. Treatment began with a 1-mg loading dose for the first 4 weeks, followed by dose escalations every 4 weeks to reach the maintenance dose of 36 mg at week 20, which was then continued for the remainder of the duration.

    Drug: Orforglipron

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    A TEAE was defined as any adverse event that began on or after the first dose of study drug or began before the first dose of study drug and worsened on or after the first dose of study drug.

    Time frame: Baseline to Week 54

Secondary outcomes

  1. Change From Baseline in Hemoglobin A1c (HbA1c)

    HbA1c is the glycosylated fraction of hemoglobin A. It is measured to identify average plasma glucose concentration over prolonged periods of time.

    Time frame: Baseline, Week 52

  2. Percentage of Participants Who Achieved HbA1c <7.0%

    HbA1c is the glycosylated fraction of hemoglobin A. It is measured to identify average plasma glucose concentration over prolonged periods of time. The reported values represent model-based estimates. The Mean (SE) is an estimated values from a logistic regression using imputed data by multiple imputation, with percentages derived by combining proportion of participants achieving target in imputed data sets using Rubin's rule.

    Time frame: Week 52

  3. Percentage of Participants Who Achieved HbA1c ≤6.5%

    HbA1c is the glycosylated fraction of hemoglobin A. It is measured to identify average plasma glucose concentration over prolonged periods of time. The reported values represent model-based estimates. The Mean (SE) is an estimated values from a logistic regression using imputed data by multiple imputation, with percentages derived by combining proportion of participants achieving target in imputed data sets using Rubin's rule.

    Time frame: Week 52

  4. Percentage of Participants Who Achieved HbA1c <5.7%

    HbA1c is the glycosylated fraction of hemoglobin A. It is measured to identify average plasma glucose concentration over prolonged periods of time. The reported values represent model-based estimates. The Mean (SE) is an estimated values from a logistic regression using imputed data by multiple imputation, with percentages derived by combining proportion of participants achieving target in imputed data sets using Rubin's rule.

    Time frame: Week 52

  5. Change From Baseline in Fasting Serum Glucose

    Time frame: Baseline, Week 52

  6. Change From Baseline in Body Weight

    Time frame: Baseline, Week 52

  7. Percentage of Participants Who Achieved Weight Loss of ≥5% From Baseline

    The reported values represent model-based estimates. The Mean (SE) is an estimated values from a logistic regression using imputed data by multiple imputation, with percentages derived by combining proportion of participants achieving target in imputed data sets using Rubin's rule.

    Time frame: Week 52

  8. Percentage of Participants Who Achieved Weight Loss of ≥10% From Baseline

    The reported values represent model-based estimates. The Mean (SE) is an estimated values from a logistic regression using imputed data by multiple imputation, with percentages derived by combining proportion of participants achieving target in imputed data sets using Rubin's rule.

    Time frame: Week 52

  9. Percentage of Participants Who Achieved Weight Loss of ≥15% From Baseline

    The reported values represent model-based estimates. The Mean (SE) is an estimated values from a logistic regression using imputed data by multiple imputation, with percentages derived by combining proportion of participants achieving target in imputed data sets using Rubin's rule.

    Time frame: Week 52

  10. Change From Baseline in Waist Circumference

    Time frame: Baseline, Week 52

  11. Change From Baseline in Body Mass Index (BMI)

    Time frame: Baseline, Week 52

  12. Change From Baseline in Daily Average 7-Point Self-Monitored Blood Glucose (SMBG)

    SMBG is measured using a glucometer. The SMBG profiles will consist of the following 7-point measurements obtained on a single day: * before 3 main meals, * approximately 2 hours after 3 main meals, and * at bedtime Daily average glucose was calculated as the mean of 7 time point specific averages obtained from up to 2 non-consecutive SMBG profiles within week 52.

    Time frame: Baseline, Week 52

07

Results

Posted Jun 30, 2026

Participant flow

Participant flow — Overall Study
Milestone3 mg Orforglipron12 mg Orforglipron36 mg Orforglipron
Started132135134
Received at least one dose of study drug132135134
Completed125128125
Not completed779
Withdrew: Adverse event263
Withdrew: Death001
Withdrew: Lost to follow-up100
Withdrew: Withdrawal by subject415

Outcome measures

PrimaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs)

A TEAE was defined as any adverse event that began on or after the first dose of study drug or began before the first dose of study drug and worsened on or after the first dose of study drug.

Time frame:
Baseline to Week 54
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Participants3 mg Orforglipron12 mg Orforglipron36 mg Orforglipron
Number of Participants With Treatment Emergent Adverse Events (TEAEs)107114118
SecondaryChange From Baseline in Hemoglobin A1c (HbA1c)

HbA1c is the glycosylated fraction of hemoglobin A. It is measured to identify average plasma glucose concentration over prolonged periods of time.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · percentage of HbA1c
Change From Baseline in Hemoglobin A1c (HbA1c)
percentage of HbA1c3 mg Orforglipron12 mg Orforglipron36 mg Orforglipron
Change From Baseline in Hemoglobin A1c (HbA1c)-1.71 ± 0.072-1.97 ± 0.075-2.13 ± 0.073
SecondaryPercentage of Participants Who Achieved HbA1c <7.0%

HbA1c is the glycosylated fraction of hemoglobin A. It is measured to identify average plasma glucose concentration over prolonged periods of time. The reported values represent model-based estimates. The Mean (SE) is an estimated values from a logistic regression using imputed data by multiple imputation, with percentages derived by combining proportion of participants achieving target in imputed data sets using Rubin's rule.

Time frame:
Week 52
Reported as:
Mean · percentage of participants
Percentage of Participants Who Achieved HbA1c <7.0%
percentage of participants3 mg Orforglipron12 mg Orforglipron36 mg Orforglipron
Percentage of Participants Who Achieved HbA1c <7.0%82.73 ± 3.2586.11 ± 2.8690.82 ± 2.52
SecondaryPercentage of Participants Who Achieved HbA1c ≤6.5%

HbA1c is the glycosylated fraction of hemoglobin A. It is measured to identify average plasma glucose concentration over prolonged periods of time. The reported values represent model-based estimates. The Mean (SE) is an estimated values from a logistic regression using imputed data by multiple imputation, with percentages derived by combining proportion of participants achieving target in imputed data sets using Rubin's rule.

Time frame:
Week 52
Reported as:
Mean · percentage of participants
Percentage of Participants Who Achieved HbA1c ≤6.5%
percentage of participants3 mg Orforglipron12 mg Orforglipron36 mg Orforglipron
Percentage of Participants Who Achieved HbA1c ≤6.5%62.64 ± 4.1176.23 ± 3.5784.56 ± 3.27
SecondaryPercentage of Participants Who Achieved HbA1c <5.7%

HbA1c is the glycosylated fraction of hemoglobin A. It is measured to identify average plasma glucose concentration over prolonged periods of time. The reported values represent model-based estimates. The Mean (SE) is an estimated values from a logistic regression using imputed data by multiple imputation, with percentages derived by combining proportion of participants achieving target in imputed data sets using Rubin's rule.

Time frame:
Week 52
Reported as:
Mean · percentage of participants
Percentage of Participants Who Achieved HbA1c <5.7%
percentage of participants3 mg Orforglipron12 mg Orforglipron36 mg Orforglipron
Percentage of Participants Who Achieved HbA1c <5.7%7.70 ± 2.2021.92 ± 3.5430.51 ± 3.86
SecondaryChange From Baseline in Fasting Serum Glucose
Time frame:
Baseline, Week 52
Reported as:
Least squares mean · milligrams per deciliter (mg/dL)
Change From Baseline in Fasting Serum Glucose
milligrams per deciliter (mg/dL)3 mg Orforglipron12 mg Orforglipron36 mg Orforglipron
Change From Baseline in Fasting Serum Glucose-51.7 ± 1.40-55.1 ± 2.86-64.5 ± 1.37
SecondaryChange From Baseline in Body Weight
Time frame:
Baseline, Week 52
Reported as:
Least squares mean · kilogram (kg)
Change From Baseline in Body Weight
kilogram (kg)3 mg Orforglipron12 mg Orforglipron36 mg Orforglipron
Change From Baseline in Body Weight-1.81 ± 0.307-5.08 ± 0.474-6.75 ± 0.509
SecondaryPercentage of Participants Who Achieved Weight Loss of ≥5% From Baseline

The reported values represent model-based estimates. The Mean (SE) is an estimated values from a logistic regression using imputed data by multiple imputation, with percentages derived by combining proportion of participants achieving target in imputed data sets using Rubin's rule.

Time frame:
Week 52
Reported as:
Mean · percentage of participants
Percentage of Participants Who Achieved Weight Loss of ≥5% From Baseline
percentage of participants3 mg Orforglipron12 mg Orforglipron36 mg Orforglipron
Percentage of Participants Who Achieved Weight Loss of ≥5% From Baseline27.00 ± 3.9049.52 ± 4.4065.14 ± 4.24
SecondaryPercentage of Participants Who Achieved Weight Loss of ≥10% From Baseline

The reported values represent model-based estimates. The Mean (SE) is an estimated values from a logistic regression using imputed data by multiple imputation, with percentages derived by combining proportion of participants achieving target in imputed data sets using Rubin's rule.

Time frame:
Week 52
Reported as:
Mean · percentage of participants
Percentage of Participants Who Achieved Weight Loss of ≥10% From Baseline
percentage of participants3 mg Orforglipron12 mg Orforglipron36 mg Orforglipron
Percentage of Participants Who Achieved Weight Loss of ≥10% From Baseline10.11 ± 2.6624.68 ± 3.7837.91 ± 4.30
SecondaryPercentage of Participants Who Achieved Weight Loss of ≥15% From Baseline

The reported values represent model-based estimates. The Mean (SE) is an estimated values from a logistic regression using imputed data by multiple imputation, with percentages derived by combining proportion of participants achieving target in imputed data sets using Rubin's rule.

Time frame:
Week 52
Reported as:
Mean · percentage of participants
Percentage of Participants Who Achieved Weight Loss of ≥15% From Baseline
percentage of participants3 mg Orforglipron12 mg Orforglipron36 mg Orforglipron
Percentage of Participants Who Achieved Weight Loss of ≥15% From Baseline2.79 ± 1.4613.96 ± 3.0720.94 ± 3.66
SecondaryChange From Baseline in Waist Circumference
Time frame:
Baseline, Week 52
Reported as:
Least squares mean · centimeter (cm)
Change From Baseline in Waist Circumference
centimeter (cm)3 mg Orforglipron12 mg Orforglipron36 mg Orforglipron
Change From Baseline in Waist Circumference-2.4 ± 0.43-4.6 ± 0.49-6.5 ± 0.54
SecondaryChange From Baseline in Body Mass Index (BMI)
Time frame:
Baseline, Week 52
Reported as:
Least squares mean · kilogram per square meter (kg/m^2)
Change From Baseline in Body Mass Index (BMI)
kilogram per square meter (kg/m^2)3 mg Orforglipron12 mg Orforglipron36 mg Orforglipron
Change From Baseline in Body Mass Index (BMI)-0.7 ± 0.12-1.9 ± 0.17-2.5 ± 0.19
SecondaryChange From Baseline in Daily Average 7-Point Self-Monitored Blood Glucose (SMBG)

SMBG is measured using a glucometer. The SMBG profiles will consist of the following 7-point measurements obtained on a single day: * before 3 main meals, * approximately 2 hours after 3 main meals, and * at bedtime Daily average glucose was calculated as the mean of 7 time point specific averages obtained from up to 2 non-consecutive SMBG profiles within week 52.

Time frame:
Baseline, Week 52
Reported as:
Mean · mg/dL
Change From Baseline in Daily Average 7-Point Self-Monitored Blood Glucose (SMBG)
mg/dL3 mg Orforglipron12 mg Orforglipron36 mg Orforglipron
Change From Baseline in Daily Average 7-Point Self-Monitored Blood Glucose (SMBG)-66.32 ± 40.622-73.14 ± 41.064-82.27 ± 39.367

Adverse events

Collected over Baseline to Week 54. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
3 mg Orforglipron0/132 (0%)4/132 (3%)106/132 (80.3%)
12 mg Orforglipron0/135 (0%)3/135 (2.2%)114/135 (84.4%)
36 mg Orforglipron1/134 (0.7%)6/134 (4.5%)118/134 (88.1%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
Event3 mg Orforglipron12 mg Orforglipron36 mg Orforglipron
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/930/971/93
PeriodontitisInfections and infestations1/1320/1350/134
Spinal osteoarthritisMusculoskeletal and connective tissue disorders1/1320/1350/134
Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1320/1350/134
LipomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1320/1350/134
Aortic stenosisVascular disorders1/1320/1350/134
CholecystocholangitisHepatobiliary disorders0/1320/1351/134
Enterocolitis bacterialInfections and infestations0/1320/1351/134
Humerus fractureInjury, poisoning and procedural complications0/1320/1351/134
DehydrationMetabolism and nutrition disorders0/1320/1351/134
Most frequent other events
Showing 10 of 283
Most frequent other events
Event3 mg Orforglipron12 mg Orforglipron36 mg Orforglipron
ConstipationGastrointestinal disorders22/13241/13539/134
NauseaGastrointestinal disorders17/13226/13537/134
NasopharyngitisInfections and infestations23/13230/13522/134
DyspepsiaGastrointestinal disorders8/13210/13518/134
VomitingGastrointestinal disorders17/13215/13517/134
DiarrhoeaGastrointestinal disorders12/13216/13516/134
Decreased appetiteMetabolism and nutrition disorders3/1326/13513/134
Covid-19Infections and infestations12/13211/13511/134
Gastrointestinal disorderGastrointestinal disorders11/1325/1357/134
Abdominal discomfortGastrointestinal disorders10/1326/1357/134

Baseline characteristics

All participants who were randomized and received at least one dose of the study drug.

Age, Continuous
Age, Continuous(years)3 mg Orforglipron12 mg Orforglipron36 mg OrforglipronTotal
Mean59.9 ± 10.358.5 ± 11.057.5 ± 10.758.6 ± 10.7
Sex: Female, Male
Sex: Female, Male(Participants)3 mg Orforglipron12 mg Orforglipron36 mg OrforglipronTotal
Female393841118
Male939793283
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)3 mg Orforglipron12 mg Orforglipron36 mg OrforglipronTotal
Hispanic or Latino0000
Not Hispanic or Latino0000
Unknown or Not Reported132135134401
Race (NIH/OMB)
Race (NIH/OMB)(Participants)3 mg Orforglipron12 mg Orforglipron36 mg OrforglipronTotal
American Indian or Alaska Native0000
Asian132135134401
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White0000
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(Participants)3 mg Orforglipron12 mg Orforglipron36 mg OrforglipronTotal
Japan132135134401
08

Study locations

40 sites
  • Nakayama Clinic
    Nagoya, Aichi-ken 456-0058, Japan
  • Shinkashiwa Clinic
    Kashiwa, Chiba 277-0084, Japan
  • Kashiwa City Hospital
    Kashiwa, Chiba 277-0825, Japan
  • Tokuyama Clinic
    Mihama-ku,Chiba City, Chiba 261-0004, Japan
  • Mikannohana Clinic, Diabetes, Endocrinology and Metabolism
    Matsuyama, Ehime 790-0034, Japan
  • Steel Memorial Yawata Hospital
    Kitakyushu, Fukuoka 805-8508, Japan
  • Hasegawa Medical Clinic
    Chitose, Hokkaido 066-0032, Japan
  • Odori Diabetes
    Sapporo, Hokkaido 060-0001, Japan
  • Matsuda Clinic
    Kobe, Hyōgo 651-2135, Japan
  • Nakamoto Internal Medicine Clinic
    Mito, Ibaraki 310-0826, Japan
  • MinamiAkatsukaClinic
    Mito, Ibaraki 311-4153, Japan
  • Nakakinen clinic
    Naka, Ibaraki 311-0113, Japan
  • Nishiyamadou Keiwa Hospital
    Naka, Ibaraki 311-0133, Japan
  • Taya Clinic Koueikai Medical Corporation
    Tsuchiura, Ibaraki 300-0047, Japan
  • Shonan Takai Clinic
    Kamakura, Kanagawa 247-0055, Japan
  • Takai Internal Medicine Clinic
    Kamakura-shi, Kanagawa 247-0056, Japan
  • Medical Corporation Yuga Tsuruma Kaneshiro Diabetes Clinic
    Yamato-shi, Kanagawa 242-0004, Japan
  • Yokohama Minoru Clinic
    Yokohama, Kanagawa 232-0064, Japan
  • Yokkaichi Diabetes Clinic
    Yokkaichi, Mie-ken 510-0829, Japan
  • Gibo Hepatology Clinic
    Matsumoto, Nagano 399-0036, Japan
  • Shiraiwa Medical Clinic
    Kashihara, Osaka 582-0005, Japan
  • Kitada Clinic
    Osaka, Osaka 538-0044, Japan
  • Medical Corporation Heishinkai OCROM Clinic
    Suita-shi, Osaka 565-0853, Japan
  • OHAMA Diabetes Clinic
    Kawaguchi, Saitama 332-0015, Japan
  • Sugiura Internal Medicine Clinic
    Sōka, Saitama 340-0015, Japan
  • Seiwa Clinic
    Adachi-ku, Tokyo 120-0011, Japan
  • The Institute for Adult Disease, Asahi Life Foundation
    Chuo-ku, Tokyo 103-0002, Japan
  • Tokyo-Eki Center-building Clinic
    Chuo-ku, Tokyo 103-0027, Japan
  • Fukuwa Clinic
    Chuo-ku, Tokyo 104-0031, Japan
  • Hachioji Diabetes Clinic
    Hachioji-shi, Tokyo 192-0083, Japan
  • Kanno Naika
    Mitaka, Tokyo 181-0013, Japan
  • Heishinkai Medical Group ToCROM Clinic
    Shinjuku-ku, Tokyo 160-0008, Japan
  • Medical Corporation Tao Internal Medicine Clinic
    Ube, Yamaguchi 755-0047, Japan
  • Fujii Clinic
    Ube, Yamaguchi 755-0049, Japan
  • Tashiro Endocrinology Clinic
    Fukuoka, 814-0153, Japan
  • Morinaga Ueno Clinic
    Kumamoto, 860-0863, Japan
  • Jinnouchi Hospital
    Kumamoto, 862-0976, Japan
  • Heiwadai Hospital
    Miyazaki, 880-0034, Japan
  • Kansai Electric Power Hospital
    Osaka, 553-0003, Japan
  • Abe Clinic
    Ōita, 870-0039, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2023 to primary completion in Jun 2025, 20 months.

Results were first posted in Jun 2026, 1 year after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 20 months is close to that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2023
First posted
Aug 24, 2023
StartActual
Sep 28, 2023
Primary completionActual
Jun 5, 2025
CompletionActual
Jun 5, 2025
Results first posted
Jun 30, 2026
Last update
Jun 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06010004
Responsible party
Sponsor
First posted
Aug 24, 2023
Start date
Sep 28, 2023
Primary completion
Jun 5, 2025
Completion
Jun 5, 2025
Results posted
Jun 30, 2026
Last update
Jun 30, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Orforglipron

Start the discussion